SCHEMBL1481346

SCHEMBL1481346

COC(=O)c1ccc(Cn2cc(-c3ccc(Cl)cc3Cl)nc2C=Cc2ccc(-c3cccc(C(F)(F)F)c3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.44
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
SIRT5 Q9NXA8 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
S1PR5 Q9H228 1/20 0.38
MAPK14 Q16539 1/20 0.38
AURKA O14965 1/20 0.38
PLG P00747 1/20 0.37
PLAU P00749 1/20 0.37
PLAT P00750 1/20 0.37
DPP4 P27487 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
NLRP3 Q96P20 1/20 0.36
TBXA2R P21731 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481344 1.00 DRD2 (0.44) DRD2POLBMAPTSIRT5SMN1; SMN2
SCHEMBL1482423 0.93 DRD2 (0.46) DRD2POLBMAPTSIRT5SMN1; SMN2
SCHEMBL1482424 0.93 DRD2 (0.46) DRD2POLBMAPTSIRT5SMN1; SMN2
SCHEMBL1676254 0.92 DRD2 (0.49) DRD2MAPTSIRT5SMN1; SMN2S1PR5
SCHEMBL1676256 0.92 DRD2 (0.49) DRD2MAPTSIRT5SMN1; SMN2S1PR5
SCHEMBL1481296 0.91 S1PR5 (0.38) DRD2MAPTS1PR5PLGPLAU
SCHEMBL1481297 0.91 S1PR5 (0.38) DRD2MAPTS1PR5PLGPLAU
SCHEMBL1481124 0.91 MEN1 (0.42) POLBSMN1; SMN2S1PR5DPP4HDAC1
SCHEMBL1481125 0.91 MEN1 (0.42) POLBSMN1; SMN2S1PR5DPP4HDAC1
SCHEMBL1482394 0.91 DRD2 (0.48) DRD2POLBMAPTPLAUNLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ DRD2 4864/4885POLB 4328/4885MAPT 3558/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE DRD2 4873/4885POLB 4497/4885MAPT 3251/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ DRD2 4864/4885POLB 4328/4885MAPT 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.